依诺肝素钠治疗急性心肌梗死的临床效果观察

Observation on the Clinical Effect of Enoxaparin Sodium in Treatment of Acute Myocardial Infarction

目的观察依诺肝素钠治疗急性心肌梗死的临床效果。方法选取2018年9月至2019年9月我院收治的102例急性心肌梗死患者,依据不同的治疗方法分为对照组和研究组,各51例。对照组采用普通肝素,研究组采用依诺肝素钠。比较两组的血脂参数(LDL-C、 HDL-C、 TC)及不良反应情况。结果给药后,研究组的LDL-C、 HDL-C、 TC水平均明显低于对照组(P <0.05)。研究组的不良反应发生率为2.0%,明显低于对照组的13.7%(P <0.05)。结论采用依诺肝素钠治疗急性心肌梗死的临床疗效显著,安全性高,值得临床推广应用。

Objective To observe the clinical effect of enoxaparin sodium in treatment of acute myocardial infarction. Methods 102 patients with acute myocardial infarction admitted to our hospital from September 2018 to September 2019 were selected and divided into control group and study group according to different treatment methods, with 51 cases in each group. The control group was treated with ordinary heparin, while the study group was treated with enoxaparin sodium. The blood lipid parameters(LDL-C, HDL-C, TC) and adverse reactions were compared between the two groups. Results After administration, the LDL-C, HDL-C and TC levels of the study group were significantly lower than those of the control group(P <0.05). The incidence of adverse reactions in the study group was 2.0%, lower than13.7% in the control group(P <0.05). Conclusions Enoxaparin sodium in the treatment of acute myocardial infarction has significant clinical efficacy and high safety, which is worthy of clinical promotion and application.